This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mamot, C. Articles by Park, J. W. Search for Related Content PubMed PubMed Citation Articles by Mamot, C. Articles by Park, J. W.

Epidermal Growth Factor Receptor (EGFR)-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRvIII-overexpressing Tumor Cells¹

Division of Hematology-Oncology [C. M., J. W. P.] and Department of Anesthesia [J. D. M.], University of California, San Francisco, and California Pacific Medical Center Research Institute, Liposome Research Laboratory [D. C. D., U. G., K. H., D. B. K.], San Francisco, California 94115

We hypothesized that immunoliposomes (ILs) that target epidermal growth factor receptor (EGFR) and/or its truncated variant EGFRvIII can be constructed to provide efficient intracellular drug delivery in tumor cells overexpressing these receptors. Monoclonal antibody fragments included Fab' fragments derived from C225, which binds both EGFR and EGFRvIII, or novel anti-EGFR scFv C10, which binds EGFR only. Monoclonal antibody fragments were covalently linked to liposomes containing various reporters or drugs. ILs were evaluated for specific binding, internalization, and cytotoxicity in EGFR/EGFRvIII-overexpressing cell lines in vitro. Flow cytometry and fluorescence microscopy showed that EGFR-targeted ILs, but not nontargeted liposomes or irrelevant ILs, were efficiently bound and internalized by EGFR-overexpressing cells, including glioma cells (U-87), carcinoma cells (A-431 and MDA-MB-468), and EGFRvIII stable transfectants (NR-6M). Furthermore, EGFR-targeted ILs did not bind to non-EGFR-overexpressing cells (MCF-7 and parental NR-6). ILs showed 3 orders of magnitude greater accumulation in NR-6-EGFRvIII stable transfectants versus parental NR-6 cells. Quantitative internalization studies indicated binding of EGFR-targeted ILs to target cells within 5 min, followed by intracellular accumulation beginning at 15 min; total uptake reached 13,000 ILs/cell. ILs were used to deliver cytotoxic drugs doxorubicin, vinorelbine, or methotrexate to EGFR/EGFRvIII-overexpressing target cells in vitro. In each case, the IL agent was significantly more cytotoxic than the corresponding nontargeted liposomal drug in target cells, whereas it was equivalent in cells lacking EGFR/EGFRvIII overexpression. We conclude that EGFR-targeted ILs provide efficient and targeted delivery of anticancer drugs in cells overexpressing EGFR or EGFRvIII.

This article has been cited by other articles:

				N. Kurata, T. Shishido, M. Muraoka, T. Tanaka, C. Ogino, H. Fukuda, and A. Kondo Specific Protein Delivery to Target Cells by Antibody-displaying Bionanocapsules J. Biochem., December 1, 2008; 144(6): 701 - 707. [Abstract] [Full Text] [PDF]

				F. An, D. C. Drummond, S. Wilson, D. B. Kirpotin, S. L. Nishimura, V. C. Broaddus, and B. Liu Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies Mol. Cancer Ther., March 1, 2008; 7(3): 569 - 578. [Abstract] [Full Text] [PDF]

				A. Roth, D. C. Drummond, F. Conrad, M. E. Hayes, D. B. Kirpotin, C. C. Benz, J. D. Marks, and B. Liu Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells Mol. Cancer Ther., October 1, 2007; 6(10): 2737 - 2746. [Abstract] [Full Text] [PDF]

				J. C. Sok, F. M. Coppelli, S. M. Thomas, M. N. Lango, S. Xi, J. L. Hunt, M. L. Freilino, M. W. Graner, C. J. Wikstrand, D. D. Bigner, et al. Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting Clin. Cancer Res., September 1, 2006; 12(17): 5064 - 5073. [Abstract] [Full Text] [PDF]

				C. Mamot, D. C. Drummond, C. O. Noble, V. Kallab, Z. Guo, K. Hong, D. B. Kirpotin, and J. W. Park Epidermal Growth Factor Receptor-Targeted Immunoliposomes Significantly Enhance the Efficacy of Multiple Anticancer Drugs In vivo Cancer Res., December 15, 2005; 65(24): 11631 - 11638. [Abstract] [Full Text] [PDF]

				Z. Li, R. Zhao, X. Wu, Y. Sun, M. Yao, J. Li, Y. Xu, and J. Gu Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics FASEB J, December 1, 2005; 19(14): 1978 - 1985. [Abstract] [Full Text] [PDF]

				D. C. Drummond, C. Marx, Z. Guo, G. Scott, C. Noble, D. Wang, M. Pallavicini, D. B. Kirpotin, and C. C. Benz Enhanced Pharmacodynamic and Antitumor Properties of a Histone Deacetylase Inhibitor Encapsulated in Liposomes or ErbB2-Targeted Immunoliposomes Clin. Cancer Res., May 1, 2005; 11(9): 3392 - 3401. [Abstract] [Full Text] [PDF]

				W. Fischer, L. Gustafsson, A.-K. Mossberg, J. Gronli, S. Mork, R. Bjerkvig, and C. Svanborg Human {alpha}-Lactalbumin Made Lethal to Tumor Cells (HAMLET) Kills Human Glioblastoma Cells in Brain Xenografts by an Apoptosis-Like Mechanism and Prolongs Survival Cancer Res., March 15, 2004; 64(6): 2105 - 2112. [Abstract] [Full Text] [PDF]